SCHEMBL3540325

SCHEMBL3540325

Cc1ncc2cc(Br)ccc2[n+]1[O-]

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 2/20 0.33
METAP2 P50579 2/20 0.33
CSNK2A1 P68400 1/20 0.33
ALDH1A1 P00352 2/20 0.33
AHR P35869 1/20 0.33
CYP2A6 P11509 1/20 0.31
GSK3A P49840 1/20 0.31
CDK9 P50750 1/20 0.31
CDK5 Q00535 1/20 0.31
TAOK1 Q7L7X3 1/20 0.31
CLK4 Q9HAZ1 1/20 0.31
ABL1 P00519 1/20 0.31
ATM Q13315 1/20 0.31
LMNA P02545 1/20 0.30
RAB9A P51151 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2C19 P33261 1/20 0.30
HTT P42858 1/20 0.30
BACE1 P56817 1/20 0.30
DYRK1A Q13627 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3535166 0.74 ATM (0.48) CYP2A6ATMRAB9ACYP1A2HTT
SCHEMBL17186135 0.73 CYP2A6 (0.39) ALDH1A1AHRCYP2A6ATMLMNA
SCHEMBL7264317 0.66 CYP2A6 (0.35) ALDH1A1CYP2A6ATMCYP1A2CYP2C19
SCHEMBL269264 0.64 CYP2A6 (0.57) NOS1METAP2CSNK2A1ALDH1A1CYP2A6
SCHEMBL6845001 0.64 CYP2A6 (0.57) NOS1METAP2CSNK2A1ALDH1A1CYP2A6
SCHEMBL6844988 0.63 BACE1 (0.46) NOS1METAP2CSNK2A1ALDH1A1CYP2A6
SCHEMBL9015199 0.63 ALOX15 (0.35) ALDH1A1AHRCYP2A6ATMRAB9A
SCHEMBL5048586 0.59 CYP1A2 (0.57) NOS1METAP2CSNK2A1ALDH1A1CYP1A2
SCHEMBL31271736 0.59 BACE1 (0.47) NOS1METAP2ALDH1A1CYP2A6GSK3A
SCHEMBL369538 0.59 CYP2A6 (0.45) ALDH1A1AHRCYP2A6ATMCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7829566-B2 Such as (7-chloro-2-styryl-quinazolin-4-yl)-(3-imidazol-1-yl-propyl)-amine; glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents MEDERSKI WERNER 2010-11-09 US disclosed
US-20070293667-A1 4-Amino-quinazolines MEDERSKI WERNER 2007-12-20 US disclosed
US-20040044204-A1 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICALS, INC. 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044204-A1 4-amino-quinazolines MRGPRX4, MRGPRX1, MRGPRX2 NOS1 3800/4885METAP2 2015/4885CSNK2A1 1732/4885
US-20070293667-A1 4-Amino-quinazolines MRGPRX4, MRGPRX1, MRGPRX2 NOS1 3105/4885METAP2 2477/4885CSNK2A1 1540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.